Tech Company Financing Transactions
AusperBio Funding Round
AusperBio, based in San Mateo, secured $50 million from CDH Investments, Genesis Capital Growth and Hankang Capital.
Transaction Overview
Company Name
Announced On
5/29/2025
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to for the ongoing clinical development of AHB-137, a novel unconjugated antisense oligonucleotide for chronic hepatitis B (CHB), including planned Phase II trials outside of mainland China.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
3 E. 3rd Ave 200
San Mateo, CA 94401
USA
San Mateo, CA 94401
USA
Phone
Website
Email Address
Overview
AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming HBV treatment for cure and advancing oligonucleotide therapeutics. Leveraging our innovative and proprietary Med-Oligo� ASO platform with effective targeted delivery technologies, we strive to unleash the power of ASO therapeutics to treat a wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases, and to transform patient lives.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Guofeng Cheng
Chief Operating Officer
Suyun Xu
Chief Scientific Officer
Chris Yang
Vice President
Hengxu Wei
VP - Bus. Development
Miao Wang
VP - Bus. Development
Xuetao Wen
VP - R & D
Yang Tian
Browse more venture capital transactions:
Prev: 5/29/2025: Gastops venture capital transaction
Next: 5/29/2025: Empathy venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on all VC transactions involving tech companies. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs